Related Experiment Video

Updated: Jun 6, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glucose-insulin-potassium therapy in adult patients undergoing cardiac surgery: a meta-analysis

Ye Fan1, An-Mei Zhang, Ying-Bin Xiao

  • 1Department of Cardiovascular Surgery, Chongqing Xinqiao Hospital, Third Military Medical University, Chongqing, China.

European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|November 16, 2010
PubMed

Insights

Glucose-insulin-potassium (GIK) therapy benefits adult cardiac surgery patients by reducing heart attacks and improving recovery. Glycemic control is key, especially for diabetic individuals undergoing GIK treatment.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Metabolic Medicine

Background:

  • Glucose-insulin-potassium (GIK) is a recognized adjuvant therapy for cardiovascular disease.
  • Previous studies on GIK in cardiac surgery have yielded controversial and inconclusive results.
  • A comprehensive meta-analysis is needed to clarify GIK's clinical efficacy in this patient population.

Purpose of the Study:

  • To determine the clinical effects of GIK therapy in adult patients undergoing cardiac surgery.
  • To synthesize evidence from randomized controlled trials (RCTs) on GIK's impact on perioperative outcomes.
  • To evaluate GIK's role in reducing myocardial injury and improving hemodynamic function.

Main Methods:

  • Systematic literature search of electronic databases and manual bibliographies.
  • Meta-analysis of 33 RCTs involving 2113 adult cardiac surgery patients.
  • Extraction and statistical summarization of data on mortality, myocardial infarction, inotropic support, atrial fibrillation, cardiac index, and hospital stay.

Main Results:

  • GIK significantly reduced perioperative myocardial infarctions (RR=0.63) and the need for inotropic support (RR=0.66).
  • Improved postoperative cardiac index (WMD=0.43) and reduced intensive care unit stay (WMD=-7.96 days) were observed.
  • Diabetic patients showed benefits with GIK and glycemic control, unlike those without glucose management.

Conclusions:

  • GIK therapy is associated with reduced myocardial injury and enhanced hemodynamic performance in cardiac surgery.
  • Effective glycemic control is crucial when administering GIK to diabetic patients undergoing cardiac surgery.
  • GIK shows promise as a beneficial adjuvant treatment, particularly when integrated with glucose management strategies.

More Related Videos

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...